2025. Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis. Journal of Carcinogenesis. 24, 10s (Dec. 2025), 382–389. DOI:https://doi.org/10.64149/J.Carcinog.24.10s.382-389.